Abstract: An inorganic fiber containing silica, alumina, one or more alkali metal oxides, and one or more of alkaline earth metal oxides, transition metal oxides, or lanthanide series metal oxides. The inorganic fiber exhibits good thermal performance at use temperatures of 1260° C. and greater, retains mechanical integrity after exposure to the use temperatures, is free of crystalline silica upon devitrification, is alkali flux resistant, exhibits low bio-persistence in an acidic medium, and exhibits low dissolution in a neutral medium. Also provided are thermal insulation products incorporating the inorganic fibers, a method for preparing the inorganic fiber and a method of thermally insulating articles using thermal insulation prepared from the inorganic fibers.

Abstract: Provided herein are compositions having a porous, architected three-dimensional geometry that are tiled to achieve increased surface area and/or volume. The tiled compositions include a plurality of tiles having seams where one of the plurality of tiles contacts an adjacent tile. Also provided herein are methods and systems for making the compositions.

Abstract: The present invention relates to the use of mixtures containing secondary calcium and secondary magnesium phosphonate for combatting harmful fungi, to the use thereof as fertilizer or plant nutrient, to a mixture, containing secondary calcium and secondary magnesium phosphonate in a specific molar ratio, characterized in that the solid form of the mixture has a water solubility of at most 5 g/l, and to a method for preparing a mixture containing secondary calcium phosphonate and secondary magnesium phosphonate.

Abstract: A maternal composition wherein said maternal composition is specifically formulated for a woman who has given birth prematurely or who is at risk of giving birth prematurely.

Abstract: The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of dermatological disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; atopic dermatitis; contact dermatitis; cholestatic itch; psoriasis; sebhorrheic dermatitis; milaria rubra; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates skin discomfort. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy of dermatological disorders.

Abstract: The present invention is a composition for increasing alcohol metabolism wherein the composition of the present invention is provided in a food substance and a drink formula. The embodiments of the composition of the present invention are operable to increase the alcohol metabolism of a user and also assist the body in burning the carbohydrates and sugars associated with alcohol consumption. The base of the composition of the present invention includes hydrous sodium aluminosilicate. Several embodiments of the present invention are provided wherein these embodiments can include some of the Vitamin B complex as well as hemp protein powder, calcium carbonate and magnesium oxide. The compositions of the present invention further include use of orthosilicates, Vitamin E, calcium, wheat grass, resveratrol, turmeric and theanine. The compositions of the present invention are provided in both liquid and solid forms.

Abstract: The purpose of the present invention is to provide a plasma spray material which is capable of forming a hydroxyapatite film that exhibits high adhesion strength with respect to substrates such as metal substrates. When used as a plasma spray material, hydroxyapatite powder having a modal diameter of 550-1000 nm in a pore diameter of at most 5000 nm as measured by a mercury intrusion method is capable of forming a hydroxyapatite film that exhibits high adhesion strength with respect to substrates such as metal substrates.

Abstract: A composition of a drug carrier, a pharmaceutical composition thereof, a preparation method and a use method thereof are provided. The composition of a drug carrier includes a first mixture and a second mixture. The first mixture includes a hydrophilic polymer, tricalcium phosphate and a water-soluble dispersant. The second mixture includes a water-absorbing material and a divalent cation salt. The pharmaceutical composition includes the composition of a drug carrier above and a drug for preparing an anti-inflammatory or antibiotic medicine. The preparation method of the composition of a drug carrier includes mixing the first mixture and the second mixture. The use method of the composition of a drug carrier includes mixing the first mixture with a drug and then adding the second mixture. Accordingly, topically applying the pharmaceutical composition on a surgical site may effectively release the drug thereon.

Abstract: A method of assessing and/or quantifying remineralization in a tooth model by exposing a tooth model to calcium and a calcium-binding fluorophore either sequentially or simultaneously under conditions sufficient to produce a remineralized/demineralized tooth model; exposing the remineralized/demineralized tooth model to a non-calcium binding fluorophore to produce an enhanced tooth model; and assessing and/or quantifying remineralization, demineralization, or both on the enhanced tooth model by determining the location and extent of calcium binding fluorophore and non-calcium binding fluorophore on the enhanced test tooth sample.

Abstract: The present invention relates generally to biocompatible medical devices, such as cranial implants, and a method and means of attaching to bone. More specifically, the present invention relates to multilayered porous material with controlled porosity and drug load designed to control the release of drugs from a medical device. Additionally the present invention provides methods for controlling release of drugs by integrating the multilayer structure in medical devices with successive layers of polymer coatings of different porosities and drug contents. The multilayer material is inserted in between two plates such as meshes that provide strength to the implant. The present invention relates to biocompatible medical devices that has osseointegration and antibacterial properties. The present invention also relates to a method and means of attaching the medical device to defect in a bone structure and comprises of tree mounting parts configured to secure the medical in place.

Abstract: Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding protein. Ribonucleic acids and interferon binding proteins can be adsorbed to the mineral layer, can be incorporated into the mineral Layer, and combinations thereof. Also disclosed are methods for co-delivery of ribonucleic acids and interferon binding proteins and methods for treating inflammatory diseases using mineral coated microparticles having a mineral layer to provide co-delivery of ribonucleic acids and interferon binding proteins.

Abstract: Composition for use in the remineralization of teeth, which comprises a fluoride-containing component and a calcium-containing component, wherein the calcium-containing component contains a nanoparticulate calcium salt and the composition is designed for the successive application of the fluoride-containing component and the calcium-containing component to the tooth surface, wherein the fluoride-containing component is applied to the tooth before the calcium-containing component.

Abstract: The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making the compositions, and methods of utilizing the same.

Abstract: In order to prevent injury from hot exhaust gas, water is condensed by a metal net in the exhaust pipe.

Abstract: A carbonate apatite highly containing carbonate groups, having excellent heavy metal adsorption capacity is provided. The carbonate apatite contains not less than 15.6% by weight carbonate groups, preferably contains at least one of copper (Cu), zinc (Zn), strontium (Sr), magnesium (Mg), potassium (K), iron (Fe), and sodium (Na), and preferably has a Ca/P molar ratio of not less than 1.5.

Abstract: A use of a vitamin composition in preparing a drug for preventing, treating, or delaying Alzheimer's disease. The composition comprises a B vitamins composition or an analog or derivative thereof, vitamin C or an analog or derivative thereof, or a combination of a B vitamins composition or an analog or derivative thereof with vitamin C or an analog or derivative thereof.

Abstract: Provided is a magnetically actuated microscaffold for minimal invasive osteochondral regeneration. More particularly, provided is a composition for cartilage regeneration, a microscaffold for cartilage regeneration, in which magnetic particles and cartilage regeneration cells are loaded on the surface of or within a 3-dimensional porous microstructure composed of a biodegradable polymer and having a diameter of 200-300 ?m; and a microscaffold for bone regeneration, in which magnetic particles and bone regeneration cells are loaded on the surface of or within a 3-dimensional porous microstructure composed of a biodegradable polymer and having a diameter of 700-900 ?m.

Abstract: Wearing a face mask or a filtering facepiece respirator, especially in hot weather for more than one hour, causes discomfort. But, in a viral pandemic, a barrier to filter inhaled and exhaled air is necessary to protect against airborne pathogens. The sensations of heat abstraction, that is, coolness and cold, can be captured by the rational design of optimized molecules. The topical application of these molecules alleviates the discomfort of wearing a face mask covering. Several entities were identified by synthesis and experiment as having the ideal properties for achieving this purpose. The preferred embodiments are certain 1-diisopropyl-phosphinoyl-alkanes described as DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds.” The applicant found that topical delivery of DIPA compounds to the facial skin, especially to the surface of the external nares (nostrils), alleviates face mask discomfort.

Abstract: Wearing a face mask or a filtering facepiece respirator, especially in hot weather for more than one hour, causes discomfort. But, in a viral pandemic, a barrier to filter inhaled and exhaled air is necessary to protect against airborne pathogens. The sensations of heat abstraction, that is, coolness and cold, can be captured by the rational design of optimized molecules called TRPM8 receptor agonists. The topical application of these molecules alleviates the discomfort of wearing a face mask covering. Several entities were identified by synthesis and experiment as having the ideal properties for achieving this purpose. The preferred embodiments are certain 1-diisopropyl-phosphinoyl-alkanes described as DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds.” The applicant found that topical delivery of DIPA compounds to the facial skin, especially to the surface of the nares (nostrils), alleviates face mask discomfort.

Abstract: Systems and methods are provided for optimizing basal administration timing in a standing basal insulin regimen of a subject. The regimen specifies a total amount of basal insulin medicament, one or more basal injection event types for a recurring period, and an apportionment of the total amount of medicament between the injection event types. Time stamped glucose measurements of the subject are obtained over a past time course comprising a plurality of instances of the recurring period. When the glucose measurements satisfy a stop condition, a recommended adjustment is determined that comprises a change in the number of injection event types in the regimen and/or a change in the apportionment of insulin medicament between injection event types. The recommended adjustment is communicated to the subject for manual adjustment of the regimen, an insulin pen charged with delivering the regimen to the subject, or a health care practitioner associated with the subject.

Abstract: A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating pain from overactive neurons. The phospholipid/inulin compositions were also shown to be effective in reducing depression and intestinal malfunctions including, but not limited to, diarrhea and constipation, and improving sleep pattern. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus.

Abstract: A pharmaceutical composition comprising tricalcium phosphate and gelatin for use in a method for the treatment of dyspepsia, acidic mouth and and/or canker sores is disclosed.

Abstract: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; iii) a non-porous ?-tricalcium phosphate powder; and iv) a porous ?-tricalcium phosphate powder. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

Abstract: A topical medication including a therapeutically effective amount of an AMPK (adenosine monophosphate-activated protein kinase) agonist for use in the treatment of one or more the human or animal medical conditions. The medical conditions include, but are not limited to: shingles (herpes zoster), post-herpetic neuralgia (PHN), gout, migraine, trigeminal neuralgia, Complex Regional Pain Syndrome (CRPS), diabetic neuropathy, peripheral neuropathy, rheumatoid arthritis, insect-related wheals, urushiol-related rash, psoriasis, herpes simplex, atopic dermatitis (eczema), contact dermatitis, allergic dermatitis, neurotrophic ulcers, first- and second-degree burns (e.g., sunburn and chemical), fibromyalgia, rubeola, and acne. Also disclosed are a method of employing the composition and a wound dressing incorporating a therapeutically effective amount of an AMPK agonist in combination with an antimicrobial agent.

Abstract: A porous material comprises at least 60 wt % of a calcium-deficient hydroxyapatite having a Ca/P molar ratio of less than 1.67, having a specific BET surface area of at least 110 m2/g and a pore volume of at least 0.41 cm3/g, both measured after heat treatment at 120° C. A catalyst composition for catalytic reduction of NOx compounds, comprising an active catalyst component: Cu and/or CuO deposited on the porous material as support. A deNOx process according to which an ammonia source is injected into a combustion waste gas stream containing NOx; and to which the catalyst composition is brought into contact with the waste gas stream at a temperature of at least 100° C. and preferably at most 600° C. to carry out, in the presence of O2, a reduction by NH3 of at least a portion of the NOx.

Abstract: A pharmaceutical composition containing cannabis for improving the quality of sleep in a patient is provided. Also provided are a use of the pharmaceutical composition for improving the quality of sleep in a patient, and methods for improving the quality of sleep. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: cannabis, and/or an herb.

Abstract: The disclosure relates to an implant material for filling bone defects, for bone regeneration, and for bone tissue engineering, to an implant comprising this material, to a method for producing such an implant, and to a method for producing a hybrid material. The implant material comprises a hybrid material comprising: a bioactive glass M based on SiO2 and CaO, optionally containing P2O5 and/or optionally doped with strontium, and a biodegradable polymer P soluble in a solvent and chosen from among bioresorbable polysaccharides. The implant material has applications in the medical field.

Abstract: Compositions of, methods of making, and methods of using alkaline earth phosphate bone cements are disclosed.

Abstract: A fast-dissolving dosage form (FDDF) for the delivery of a vaccine is prepared using a formulation containing a starch, optionally, along with at least one additional matrix forming agent, preferably, a combination of gelatin and mannitol, where an immune response is induced in a patient in need thereof.

Abstract: A method for prophylactic treatment of ketosis in a calving cow, the method including orally administering to the cow within a time period of about 12 hours after calving an effective dose of from 20 to 30 g of rumen protected methionine. If the cow falls into a risk category, the cow is administered the dose of rumen protected methionine once a day on the second, third, fourth, and fifth days after calving. Also, a composition including a gelatin capsule and rumen-protected methionine contained within the gelatin capsule that may be administered to a calving cow for the prophylactic treatment of ketosis. The composition may further contain within the gelatin capsule one or more other compounds known to have efficacy on fat or glucose metabolism, such as glucose, propylene glycol, niacin, choline, chromium, calcium propionate, and glucocorticoids.

Abstract: Calcium-containing compounds have been at least partly film-coated and/or granulated with a water-soluble substance and a water-soluble polymeric substance and use of such coated compounds in pharmaceutical compositions. The at least partly film-coated and/or granulated calcium-containing compounds have proved suitable for the preparation of tablets having a very high load of elemental calcium and a conveniently small size. A drug load of about 96% or more is obtained in tablets of the invention that have sufficient mechanical and organoleptic properties.

Abstract: The disclosure features compositions that include a material featuring three calcium phosphate phases that form one or more integral units of a solid, where a first one of the three phases includes one or more regions formed of hydroxyapatite, a second one of the three phases includes one or more regions formed of ?-tricalcium phosphate, a third one of the three phases includes one or more regions formed of amorphous calcium phosphate, and where at least some of the regions corresponding to the first, second, and third phases contact one another in the one or more integral units of the solid.

Abstract: To manufacture the implant a nanopowder of synthetic hydroxyapatite (Hap) is used having a hexagonal structure, average grain size in a range from 3 to 30 nm and the specific surface area greater than 200 m2/g. First the nanopowder is formed to the desired geometric shape, and then the shape is fixed. In the step of shape information the dried nanopowder is pressed in the mold under the pressure ranging from 50 Mpa to 2 GPa. In the step of fixing the pressed nanopowder at room temperature is subjected to the pressure rising from the ambient value to the peak value selected from a range of 1 to 8 GPa and to a temperature selected from a range of 100° C. to 600° C. for a period of time selected from a range from 30 seconds to 5 minutes. The density of thus produced implant, determined by helium method, is not less than 75% of the theoretical density.

Abstract: Methods and articles of manufacture for treating patients with degenerative bone are provided. The methods are useful to improve bone quality in a localized area of a degenerative bone (e.g., osteopenic or osteoporotic bone), such as by improving BMD to be substantially similar to BMD in an average, healthy individual at the age of peak BMD. The methods can comprise forming a void in a localized area of the degenerative bone and filling the void with a bone regenerative material that causes generation of new, healthy, natural bone material. The articles of manufacture can comprise kits formed of various materials useful in the inventive methods for improving bone quality.

Abstract: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; iii) a non-porous ?-tricalcium phosphate powder; and iv) a porous ?-tricalcium phosphate powder. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

Abstract: The present invention provides methods for inhibiting complement activation and uses thereof. More specifically, the present invention provides methods for inhibiting complement activation using inorganic polyphosphates of at least 10 phosphate units. The polyphosphates inhibit complement activation by one or more of: binding to the C6 complement protein, C1-esterase inhibitor (C1-inh), factor H or factor B; enhancing the activity of C1-inh; interfering with C1s-mediated cleavage of C2; destabilizing the C5b-6 complement protein complex; interfering with C5b,6 interaction with C7; interfering with binding of C5b-7 to a cell membrane; interfering with integration of C5b-7 into a cell membrane; interfering with binding of C5b-8 to a cell membrane; interfering with integration of C5b-8 into a cell membrane; destabilizing the membrane attack complex (MAC); or reducing the amount of C5b-9 deposited on a cell surface.

Abstract: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, including i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; and iii) a ?-tricalcium phosphate powder having a median particle size of less than about 20 microns. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

Abstract: The present invention relates to compositions and methods useful for treating structures of the vertebral column, including vertebral bodies. In one embodiment, a method for promoting bone formation in a vertebral body comprising providing a composition comprising a PDGF solution and a biocompatible matrix and applying the composition to at least one vertebral body. Promoting bone formation in a vertebral body, according to some embodiments, can increase bone volume, mass, and/or density leading to an increase in mechanical strength of the vertebral body treated with a composition of the present invention.

Abstract: Compositions of reducing agents and carriers for producing a stable negative oxidation reduction potential in consumable materials are disclosed and claimed. Compositions of the invention find use in enhancing the hydration and anti-oxidant value of consumable materials such as foods, beverages and cosmetics, for example. Compositions of the invention also find use in water treatment, agricultural and scientific research applications. Methods for using and making the compositions are also within the scope of the invention.

Abstract: The bone repair material comprises the following components: A) a first granular component with a diameter larger than 20 ?m chosen from the group of: calcium phosphate, calcium pyrophosphate, or calcium sulfate dihydrate; B) a second component chosen from the group of apatite powder with a particle diameter smaller than 1 ?m, (preferably smaller than 100 nm); and B) a third component comprising water or an aqueous solution, whereby C) the volume fraction of the second and third component represents at least 35 volume-% of the total bone repair material.

Abstract: The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof.

Abstract: The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking.

Abstract: The present invention generally relates to the field of bone substitute materials, and particularly to a bone substitute material that is bioactivated. More specifically, the present invention relates to a particular agent comprising citrate, citric acid, monobasic sodium phosphate, dextrose, and adenine for use in improving or promoting osseointegration of a bone substitute material, to a bone substitute material provided with a coating of said particular agent, and to a kit for use in a method of installing a bone substitute material comprising a bone substitute material as well as citrate, citric acid, monobasic sodium phosphate, dextrose, and adenine.

Abstract: It is intended to provide a remineralization promoter for tooth enamel and a composition for an oral cavity, which can highly effectively promote the remineralization of tooth enamel and strongly inhibit dental caries. The remineralization promoter for tooth enamel and the composition for an oral cavity are characterized by containing amorphous hydroxyapatite and/or amorphized hydroxyapatite showing two peaks at 2?=31 to 35° in X-ray diffraction. The amorphized hydroxyapatite is obtained by reacting calcium salt with phosphate in an aqueous solution and drying the reaction solution at a temperature of 10 to 70° C.

Abstract: A biomaterial in which the surface of a metal base is coated with a coating agent containing a composite of hydroxyapatite and collagen in which the c-axis of hydroxyapatite in the composite is oriented along collagen fibers is used.

Abstract: A feed supplement mixture for performance horses provides a high protein nutritional supply while lowering stress experienced by the horse, reduces the onset of ulcers in the horse's digestive tract and treats ulcers in horses already afflicted with ulcers by the introduction of a quantity of thiamine to reduce stress and sodium bicarbonate to raise the ph level of the feed and the horse's stomach content.

Abstract: There is provided a bone filler material comprising a plurality of particles, each particle comprising a biodegradable outer shell and an inner core. There is also provided an implant prepared from the same, methods of using the same and preparing the same.

Abstract: Disclosed are various bioactive grafts and/or biocompatible materials and methods of making the same. In one embodiment, bone material is harvested from a donor. The harvested bone material is exposed to a lysing agent, the lysing agent configured to release growth factors and bioactive materials from cellular material of the harvested bone material. The harvested bone material is then rinsed with a rinsing agent. The pH of the harvested bone material is substantially neutralized. In another embodiment, an orthopedic implant includes an antibacterial polysaccharide. The implant may also include an osteostimulative agent.

Abstract: An apparatus for mineralising a biological material includes an ultrasonic source, operable to generate an ultrasonic signal, an ultrasonic probe and one or more mineralising probes, operable to receive a mineralising agent. The mineralising agent is transferred from at least one mineralising probe to the biological material using the ultrasonic signal. Also disclosed are a mineralisation agent and a method of mineralising a biological material that includes the steps of: providing an ultrasound source, providing a mineralising agent, generating an ultrasonic signal from the ultrasound source, and applying the ultrasonic signal and the mineralising agent to the biological material separately, sequentially or simultaneously.

Abstract: A process of preparing a glass comprising: (a) heating a mixture of precursor chemicals to a melt temperature to form a melt, the melt being characterized in that quenching the melt at or above a threshold temperature results in a spinodal phase seperation, and quenching the melt below the threshold temperature results in a droplet phase seperation; and (b) quenching the melt at or above the threshold temperature in a preheated mold to form the glass composition having the spinodal phase seperation.